LPTX Leap Therapeutics
- 2.4700
- -0.0250-1.00%
Leap Therapeutics News
Buy Rating Affirmed for Leap Therapeutics on Strong Trial Prospects and Solid Financials
Leap Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Leap Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : Maintaining the Leap Therapeutics (LPTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $5.50.
HC Wainwright & Co. : Maintaining the Leap Therapeutics (LPTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $5.50.
HC Wainwright & Co. Maintains Buy on Leap Therapeutics, Lowers Price Target to $5.5
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Leap Therapeutics (NASDAQ:LPTX) with a Buy and lowers the price target from $7 to $5.5.
Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress
Leap Therapeutics Says Net Proceeds From April 2024 $37.2M Financing, Combined With Existing Cash, Cash Equivalents And Marketable Securities Of $54.9M, Are Expected To Provide Cash Runway Into The Second Quarter Of 2026
Leap Therapeutics Says Net Proceeds From April 2024 $37.2M Financing, Combined With Existing Cash, Cash Equivalents And Marketable Securities Of $54.9M, Are Expected To Provide Cash Runway Into The Se
Leap Therapeutics Q1 2024 GAAP EPS $(0.51) Beats $(0.58) Estimate
Leap Therapeutics Q1 2024 GAAP EPS $(0.51) Beats $(0.58) Estimate
Press Release: Leap Therapeutics Reports First Quarter 2024 Financial Results
Leap Therapeutics Reports First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass., May 13, 2024 CAMBRIDGE, Mass., May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a bio
Leap Therapeutics 1Q Loss/Shr 51c >LPTX
Leap Therapeutics 1Q Loss/Shr 51c >LPTX
Leap Therapeutics | 10-Q: Quarterly report
Leap Therapeutics Reports First Quarter 2024 Financial Results
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024.
Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024
Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024
Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler
Leap Therapeutics To Sell $40 Mln Of Shares In Private Placement; Stock Up Over 14%
Press Release: Leap Therapeutics Announces $40 Million Private Placement
Leap Therapeutics Announces $40 Million Private Placement PR Newswire CAMBRIDGE, Mass., April 11, 2024 Net proceeds, along with existing cash, cash equivalents, and marketable securities are expect
Leap Therapeutics Announces $40 Million Private Placement
Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and developme
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersXTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 13.9% to $2.71 during Wednesday's after-market session. The market value of their outstanding shares is at $14.7 million. Leap Thera
Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating
Leap Therapeutics (LPTX) has an average outperform rating and price target range of $7 to $16, according to analysts polled by Capital IQ.
Leap Therapeutics Is Maintained at Outperform by Baird
Leap Therapeutics Is Maintained at Outperform by Baird
Baird Maintains Outperform on Leap Therapeutics, Lowers Price Target to $9
Baird analyst Joel Beatty maintains Leap Therapeutics (NASDAQ:LPTX) with a Outperform and lowers the price target from $11 to $9.
Analysis
Price Target
No Data
